Why choose Alfakjn as your distribution partner
Introducing a new brand to the portfolio is a decision with long-term consequences: for the distributor's image, its ability to differentiate itself, and its day-to-day operational management. It is not a choice made on the basis of a price list or a sales presentation.
Alfakjn knows this. That is why it works with a limited number of partners per country, selected on the basis of market consistency and alignment on development expectations. If you are considering whether Alfakjn is right for you, the next four sections will answer what a qualified buyer really asks.
Four dimensions for evaluating a partnership
Product differentiation
The first question a distributor asks when faced with a new brand is: does this product help me stand out, or does it overlap with what I already have?
The Alfakjn response is built on three levels.
- proprietary formulations developed in-house, not products licensed from third parties.
- active patents covering exclusive therapeutic combinations — the patent underlying the Joyflex Proakjn formulation on the Sodium hyaluronate and Methylsulfonylmethane combination, which offers the viscosupplementation-prolotherapy pairing, is the most relevant case.
- therapeutic areas chosen with discernment, where the clinical need is real and the room for differentiation is still open.
Operational reliability
The second evaluation criterion is continuity: a product that enters a market must be able to stay there.
This means a stable supply chain, internal regulatory management, and constantly updated documentation.
Alfakjn manufactures in Italy, with direct oversight of development and production. Its nine active certifications cover process quality and regulatory compliance. Compliance with the European MDR and its listing on EUDAMED are managed in-house.
For the distributor: fewer risks of interruption, fewer surprises regarding documentation, more predictability in the operational relationship.
Business opportunity
The third axis is the economic one: is including Alfakjn worth the introduction cost?
The answer depends on three factors.
Product positioning makes it possible to escape the price war on equivalent commodities; whoever sells Joyflex Proakjn is not selling an interchangeable product.
Structuring the portfolio by therapeutic area makes it possible to build a presence in segments where clinical demand is structural.
The agreement structure is defined on a case-by-case basis, depending on the country, the distributor's profile and the therapeutic areas of interest; there is no single predefined method.
Partnership model
The fourth pillar answers the question: how do you work with Alfakjn?
The answer is: in a structured, but not rigid, way.
Alfakjn supplies technical and commercial materials, supports the distributor in understanding the product for their market, and is available to adapt positioning to different distribution contexts, while maintaining scientific and regulatory consistency.
There is no centralised, distant management model: the Alfakjn team is accessible, and the relationship with the partner is built over time based on shared objectives.
Not all markets are the same. Neither are distributors.
Alfakjn evaluates every potential partnership on the basis of precise criteria: knowledge of the local market, the ability to reach key professionals in the therapeutic area, the sales structure, and portfolio alignment with the Alfakjn proposal.
We are not looking for the distributor with the highest number of product lines. We are looking for the right partner for each market: someone who can make Alfakjn a recognisable presence in their own country, not just an addition to the catalogue.
